| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_142204a88c5dd416a910c79ef38eb4b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78941ed5a01bfbcd48376e1fdb485b19 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2010-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d39366e55c99bf91e5721f69f3271dc |
| publicationDate |
2010-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010124239-A2 |
| titleOfInvention |
Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer |
| abstract |
The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with topoisomerase inhibitor therapy or anti-EGFR and topoisomerase inhibitor therapy combination therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018235937-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109554465-A |
| priorityDate |
2009-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |